Alivus Life Sciences Limited — Updates, 24-10-2024: Press Release

Glenmark Life Sciences Limited reported Q2FY25 revenue of Rs. 5,069 million, with gross margins rising to 55.6%. However, the company experienced a 6.7% year-over-year decline in revenue for H1FY25. EBITDA for H1FY25 was Rs. 3,079 million, down 16.2% YoY, while PAT stood at Rs. 953 million for Q2. Management anticipates improved performance in H2FY25, supported by a solid order book and operational expansions, despite a temporary facility closure affecting earlier results.